These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 32002809)

  • 1. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
    Takeda T; Takeuchi M; Saitoh M; Takeda S
    Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
    Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
    PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
    BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.
    Zer A; Sung MR; Walia P; Khoja L; Maganti M; Labbe C; Shepherd FA; Bradbury PA; Feld R; Liu G; Iazzi M; Zawisza D; Nouriany N; Leighl NB
    Clin Lung Cancer; 2018 Sep; 19(5):426-434.e1. PubMed ID: 29803574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
    Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: A Single Institutional Cohort Study.
    Yuan Q; Xu C; Wang W; Zhang Q
    Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
    Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
    Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
    Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
    Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
    Park W; Mezquita L; Okabe N; Chae YK; Kwon D; Saravia D; Auclin E; Planchard D; Caramella C; Ferrara R; Agte S; Oh M; Mudad R; Jahanzeb M; Suzuki H; Besse B; Lopes G
    Br J Cancer; 2020 Feb; 122(3):340-347. PubMed ID: 31761899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
    Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
    Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
    Cancer Med; 2018 Jan; 7(1):13-20. PubMed ID: 29150906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.